The thrombocytopenia treatment market is driven by increasing prevalence of thrombocytopenia globally.
Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequency of thrombocytopenia is higher for people aged 60 years and above, suffering from non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone thrombopoietin has resulted in new treatment opportunities for clinical manifestation.
Click To Continue Reading on Thrombocytopenia Treatment Market
More specific treatment plans usually depend on the underlying etiology of thrombocytopenia. In most cases the underlying cause of thrombocytopenia is not known, especially in the case of severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist developed by Shionogi Inc., received approval by Pharmaceuticals and Medical Devices Agency of Japan. Lusutrombopag helped enhance chronic liver disease (CLD) associated with thrombocytopenia for patients scheduled to undergo invasive procedures.
Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow cells into megakaryocytes. Thus, increasing the blood platelet count. However, patients treated with Lusustrombopag further showed higher counts of blood leukocytes and erythrocyte. Furthermore, in June 2017, FDA accepted application for new oral investigational drug, Tavalisse (fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designed to inhibit the spleen tyrosine kinase and treat patients suffering from chronic or persistent immune thrombocytopenia.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1484
Key Vendors:
3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.
Contact Us:
Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org/
Aspergillosis Treatment Market Opportunity Analysis, 2018-2026
Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market.Measles Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2018 – 2026
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines.PoC Platform & Technology Market to Surpass US$ 45.4 Billion by 2025
The global POC platform & technology market was valued at US$ 21,370.3 Million in 2016 and is expected to exhibit a robust CAGR of 8.9% over the forecast period (2017 – 2025).